References
- Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53–62.
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
- Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23:529–45.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
- Hauschild A, Grob JJ, Demidov LV, et al . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.
- Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103–9.
- Chan W, Vorobiof DA . Dupuytren's contractures associated with the BRAF inhibitor vemurafenib: a case report. J Med Case Rep. 2015;9:158.
- Sibaud V, Chevreau C . Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib. Joint Bone Spine. 2014;81:373–4.
- Patel M, Freeman NR, Dhaliwal S, et al. The prevalence of Dupuytren contractures in patients with psoriasis. Clin Exp Dermatol. 2014;39:894–9.
- Blandizzi C, Gionchetti A, Armuzzi A, et al. The role of tumor necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27:1–10.
- Verjee LS, Verhoekx JS, Chan JK, et al . Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci USA. 2013;110:E928–37.
- Wilmott JS, Haydu LE, Menzies AM, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol. 2014;192:2505–13.
- Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.
- Mavropoulos A, Rigopoulou EI, Liaskos C, et al. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol. 2013;2013:569751.
- Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:320–44.